Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2855 - Real-world use of docetaxel for metastatic castration-resistant prostate cancer in China: results from a large observational study

Date

10 Sep 2017

Session

Poster display session

Topics

Cytotoxic Therapy;  Prostate Cancer

Presenters

Dalin He

Citation

Annals of Oncology (2017) 28 (suppl_5): v269-v294. 10.1093/annonc/mdx370

Authors

D. He1, Z. Sun2, J. Guo3, Z. Zhang4, Y. Shan5, L. Ma6, H. Li7, J. Jin8, Y. Huang9, J. Xiao10, Q. Wei11, D. Ye12

Author affiliations

  • 1 Department Of Urology, The First Affiliated Hospital of Xi’an Jiaotong University, 710061 - Xi'an/CN
  • 2 Department Of Urology, Huadong Hospital Affiliated to Fudan University, shanghai/CN
  • 3 Department Of Urology, Zhongshan Hospital, Fudan University, shanghai/CN
  • 4 Department Of Urology, Sir Run Run Shaw Hospital Zhejiang University School of Medicine, Hangzhou/CN
  • 5 Department Of Surgery/urology, The Second Affiliated Hospital of Soochow University, Suzhou/CN
  • 6 Department Of Urology, The Third Hospital of Peking University, Beijing/CN
  • 7 Department Of Urology, Peking Union Medical College Hospital, Beijing/CN
  • 8 Department Of Urology, Peking University First Hospital, Beijing/CN
  • 9 Department Of Urology, Renji Hospital Shanghai Jiaotong University School of Medicine, Shanghai/CN
  • 10 Department Of Urology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou/CN
  • 11 Department Of Urology, West China Hospital, Sichuan University, Chengdu/CN
  • 12 Department Of Urology, Fudan University Shanghai Cancer Center, Shanghai/CN
More

Resources

Abstract 2855

Background

This study investigated real-world patterns of docetaxel use for metastatic castration-resistant prostate cancer (mCRPC) in China.

Methods

A prospective, multi-centre, observational study of Chinese adults (≥18 years) with histologically confirmed metastatic prostate adenocarcinoma who received ≥1 dose of docetaxel following hormonal therapy failure (disease progression and serum testosterone

Results

From August 2011 to June 2016, 403 patients were enrolled at 32 centres and 315 (78.2%) completed the study. The mean number of docetaxel cycles and dose were 4.4 (2.86) and 66.9 mg/m2 (9.12), and treatment compliance was 94.0% (10.94%). mOS was similar for docetaxel after 1st- or 2nd-line hormonal therapy (Table), and was longer in patients without visceral metastases versus those with visceral metastases (23.3 months vs. 17.4 months, P = 0.019). Planned docetaxel treatment was completed by 30.8% (124) of patients; the most common reasons for discontinuation were ‘other reasons’ (23.3% [94]), cost of medical expenses (22.6% [91]), and tumor progression (14.1% [57]). Treatment-emergent AEs (TEAEs) occurred in 20.8% (84), and serious TEAEs in 4% (16), of patients.Table:

813P

Pattern of use of docetaxel in Chinese patients with mCRPCn (%)Median overall survival, months (95% CI)PSA response rate, % (n/na)
All patients403 (100)22.4 (20.4, 25.8)70.9 (168/237)
After failure of 1st-line hormonal therapy170 (42.2)22.5 (19.2, 29.5)b73.6 (64/87)
After failure of 2nd-line hormonal therapy125 (31.0)23.3 (18.1, 26.5)b67.1 (55/82)
After failure of ≥ 3rd-line hormonal therapy51 (12.7)22.4 (19.0, 36.5)65.4 (17/26)
After failure of estramustine therapy46 (11.4)20.2 (16.6, 27.7)69.7 (23/33)
Other11 (2.7)28.6 (17.5, not evaluable)100.0 (9/9)
a

Denominator is the number of patients in each category who had PSA ≥20 ng/ml at baseline;

b

p = 0.781 for median overall survival with initiation of docetaxel following failure of 1st- and 2nd-line hormonal therapy. mCRPC, metastatic castration-resistant prostate cancer; PSA, prostate specific antigen.

Conclusions

Around three-quarters of Chinese mCRPC patients treated with docetaxel initiate treatment after failure of 1st- or 2nd-line hormonal therapy and mOS and PSA RR are similar in both settings. Docetaxel was relatively well tolerated.

Clinical trial identification

Legal entity responsible for the study

Sanofi-Aventis

Funding

Sanofi-Aventis

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.